GOLGA8G Inhibitors
GOLGA8G inhibitors represent a chemical class specifically designed to interfere with the function of the GOLGA8G protein. GOLGA8G, a member of the golgin subfamily of proteins, is implicated in the maintenance of the Golgi apparatus structure and function, which is crucial for proper cellular trafficking and protein modification. These inhibitors act by disrupting the interaction between GOLGA8G and other molecular partners or by impeding the protein's ability to bind to the Golgi membrane, thereby compromising its structural integrity. The inhibition of GOLGA8G can affect the tethering of vesicles and transport intermediates, impede the intra-Golgi transport, and disrupt the cisternal maturation process. The targeted action of GOLGA8G inhibitors is of particular interest in the study of cellular transport mechanisms, as they provide a means to dissect the role of GOLGA8G in Golgi apparatus function and its impact on the overall cellular secretory pathway.
The specificity of GOLGA8G inhibitors allows researchers to probe the dynamic processes of vesicular trafficking with precision. By inhibiting GOLGA8G, these compounds contribute to a cascade of effects that can lead to the accumulation of proteins within the Golgi, altered glycosylation patterns, and even Golgi fragmentation. The direct inhibition of GOLGA8G can elucidate the protein's role in maintaining Golgi architecture and its relationship with microtubule dynamics, as well as the spatial organization of Golgi enzymes, which are critical for the sequential processing of cargo proteins. GOLGA8G inhibitors, therefore, are vital tools in cell biology, helping to unravel the complex web of interactions and dependencies that characterize the secretory pathway of eukaryotic cells and contribute to our understanding of cellular homeostasis and protein trafficking fidelity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts Golgi structure and function by inhibiting the ADP-ribosylation factor (ARF), a small GTPase essential for maintaining Golgi apparatus integrity. As GOLGA8G is a Golgi-associated protein, Brefeldin A's action indirectly leads to the functional inhibition of GOLGA8G by compromising its structural context. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A is a specific inhibitor of the Golgi BFA resistance factor 1 (GBF1), a GTPase involved in Golgi trafficking. By inhibiting GBF1, Golgicide A causes a disassembly of the Golgi apparatus, thereby indirectly inhibiting GOLGA8G by affecting its localization and stability. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that disrupts Golgi function by altering cation exchange, particularly Na+/H+ exchange, leading to Golgi pH alteration. This pH change can indirectly inhibit GOLGA8G by affecting the protein's folding and trafficking within the Golgi. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubule polymerization, leading to Golgi fragmentation. As GOLGA8G requires an intact microtubule network for proper localization, nocodazole indirectly inhibits the function of GOLGA8G through cytoskeletal disruption. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore is a GTPase inhibitor that targets dynamin, crucial for vesicle scission from the Golgi. Inhibition of dynamin function impairs vesicular trafficking, which is essential for GOLGA8G function, leading to its indirect inhibition. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation in the ER, leading to protein misfolding and ER stress. Due to the reliance of GOLGA8G on proper glycosylation for its function, tunicamycin indirectly inhibits GOLGA8G by impeding its post-translational modification. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $117.00 $344.00 | 3 | |
Betulinic Acid induces autophagy and can lead to the degradation of cellular components, including the Golgi apparatus. The induction of autophagy can, therefore, indirectly inhibit GOLGA8G by promoting its degradation. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a selective inhibitor of Cdc42, a member of the Rho family of GTPases involved in actin cytoskeleton dynamics. Inhibition of Cdc42 indirectly affects GOLGA8G by destabilizing the actin cytoskeleton, thereby impeding intracellular transport and localization of GOLGA8G. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
SecinH3 inhibits cytohesins, which are ARF GTPase exchange factors, leading to disruption of ARF-mediated Golgi function. As a consequence, the inhibition of cytohesins indirectly leads to the inhibition of GOLGA8G by affecting the Golgi apparatus where GOLGA8G functions. | ||||||